Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease

BACKGROUND: Vedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn’s disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment. METHODS: Sera at weeks...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Therap Adv Gastroenterol
Autors principals: Holmer, Ariela K., Battat, Robert, Dulai, Parambir S., Vande Casteele, Niels, Nguyen, Nghia, Jain, Anjali, Miralles, Ara, Neill, Jennifer, Le, Helen, Singh, Siddharth, Rivera-Nieves, Jesus, Sandborn, William J., Boland, Brigid S.
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7675888/
https://ncbi.nlm.nih.gov/pubmed/33240396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284820971214
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars